Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Technology Stocks & Market Talk With Don Wolanchuk -- Ignore unavailable to you. Want to Upgrade?

To: da_cheif™ who wrote (188276)	3/29/2023 3:59:30 PM
From: Winfastorlose	1 Recommendation Recommended By Mick Mørmøny Respond to of 207846

What an analyst. :) Jefferies Keeps Their Buy Rating on Vaxart (VXRT) Howard Kim Mar 29, 2023, 05:15 AM In a report released yesterday, Roger Song from Jefferies maintained a Buy rating on Vaxart ( VXRT – Research Report), with a price target of $10.00. The company’s shares closed yesterday at $0.75. According to TipRanks, Song is an analyst with an average return of -27.2% and a 21.33% success rate. Song covers the Healthcare sector, focusing on stocks such as Aclaris Therapeutics, Aadi Bioscience, and Nektar Therapeutics. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Vaxart with a $5.75 average price target.

To: da_cheif™ who wrote (188276)	3/29/2023 4:03:20 PM
From: kwills	Respond to of 207846

Agreed... have to take the month end gravy on semis... After 4000 support failed yesterday it was regained late in the session, a sign of strength. Upside target is 4100.